✦ LIBER ✦

CCI-779 in metastatic melanoma : A Phase II trial of the California Cancer Consortium

✍ Scribed by Kim Margolin; Jeffrey Longmate; Tracey Baratta; Tim Synold; Scott Christensen; Jeffrey Weber; Thomas Gajewski; Ian Quirt; James H. Doroshow

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 67 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21265

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of taxol in metastatic

A phase II trial of taxol in metastatic melanoma

✍ Sewa S. Legha; Sigrid Ring; Nicholas Papadopoulos; Martin Raber; Robert S. Benja 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 2 views

A phase II trial of arsenic trioxide in

A phase II trial of arsenic trioxide in patients with metastatic melanoma

✍ Kevin B. Kim; Agop Y. Bedikian; Luis H. Camacho; Nicholas E. Papadopoulos; Cecil 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 2 views

A phase 2 study of temsirolimus (CCI-779

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas : A study of the Mayo phase 2 consortium (P2C)

✍ Scott Okuno; Howard Bailey; Michelle R. Mahoney; Douglas Adkins; William Maples; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 1 views

Phase II trial of doxorubicin and triflu

Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer

✍ G. T. Budd; R. M. Bukowski; A. Lichtin; L. Bauer; P. Kirk; R. Ganapathi 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 361 KB

Bevacizumab and everolimus in the treatm

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma : A phase 2 trial of the Sarah Cannon Oncology Research Consortium

✍ John D. Hainsworth; Jeffrey R. Infante; David R. Spigel; James D. Peyton; Dana S 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 2 views

Trastuzumab plus docetaxel in HER-2/neu-

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma : Final results from the California Cancer Consortium screening and Phase II trial

✍ Primo N. Lara Jr.; Karen Giselle Chee; Jeff Longmate; Christopher Ruel; Frederic 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## BACKGROUND Overexpression of the HER‐2/__neu__ oncoprotein has been reported to occur in ≤ 60% of patients with prostate carcinoma and to correlate with shortened survival. Trastuzumab is a humanized monoclonal antibody to the HER‐2 receptor and has activity against HER‐2–positive b